Bispecific Therapy in Refractory Multiple Myeloma in the Octogenarian Population

Key Points

• Bispecific therapy shows improved efficacy in refractory multiple myeloma patients over the age of 80.
• A key metric includes a response rate of 55%, observed within 6 months of treatment initiation.
• Assessment included clinical responses and biomarkers associated with patient outcomes.
• This study highlights the need for tailored therapies in the octogenarian population, with further research needed.